Background/Aims: An association of genetic variants of homocysteine (Hcy) metabolic genes with type 2 diabetes mellitus (T2DM) has been reported. The objective of the present study was to investigate the relationship between the genetic variants in Hcy metabolism-related genes and plasma Hcy levels and T2DM susceptibility in Han Chinese. Methods: A total of 774 patients with T2DM and 500 healthy individuals were recruited. Single-nucleotide polymorphism was determined by standard methods. Results: The Hcy-increasing allele score was positively associated with plasma Hcy levels in both T2DM patients and healthy subjects (r = 0.171 and 0.247, respectively). Subjects with the genotype CC of MTHFR (rs1801131) had a significantly higher likelihood of T2DM compared with subjects with the AA or AA+AC genotypes (OR = 1.93 for CC vs. AA, p = 0.041; OR = 3.13 for CC vs. AA+AC, p = 0.017, respectively). Subjects with the genotype AA of the MTHFD variant (rs2236225) had a significantly lower likelihood of T2DM compared with subjects with the GG or GG+GA genotypes (OR = 0.36 for AA vs. GG, p = 0.027; OR = 0.36 for AA vs. GG+GA, p = 0.017, respectively). In addition, the genotype CT+TT of the PEMT (rs4646356) variants displayed a significant association with an increased risk of T2DM (OR = 1.52 for CT+TT vs. CC, p = 0.042). Conclusions:MTHFR rs1801131 C allele and PEMT rs4646356 T allele were associated with a high risk of T2DM in these Han Chinese.

Keywords:
Methionine, Homocysteine, Type 2 diabetes mellitus, Single nucleotide polymorphisms
1.
Huang T, Yuan GF, Zhang ZG, Zou ZQ, Li D: Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr 2008;17:8-16.
2.
Chauhan G, Kaur I, Tabassum R, Dwivedi OP, Ghosh S, Tandon N, Bharadwaj D: Common variants of homocysteine metabolism pathway genes and risk of type 2 diabetes and related traits in Indians. Exp Diabetes Res 2012;2012:960318.
3.
Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, Smith CE, Ordovas JM, Li D, Lai CQ: Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in Puerto Rican adults. J Nutr 2011;141:654-659.
4.
Huang T, Tucker KL, Crott J, Parnell LD, Li D, Ordovas JM, Lai CQ: MTHFR 1298 A>C interacts with polyunsaturated fatty acid to modulate plasma homocystine in Boston Puerto Rican. Ann Nutr Metab 2009;55:324-325.
5.
Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, Halsted CH: Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 2000;9:2837-2844.
6.
Huang T, Tucker K, Lee Y, Crott J, Parnell L, Shen J, Smith C, Ordovas J, Li D, Lai C: MAT1A variants modulate the effect of dietary fatty acids on plasma homocysteine concentrations. Nutr Metab Cardiovasc Dis 2012;22:362-368.
7.
Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310-315.
8.
Namour F, Olivier J, Abdelmouttaleb I, Adjalla C, Debard R, Salvat C, Gueant J: Transcobalamin codon 259 polymorphism in Ht-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood 2001;97:1092-1098.
9.
Lai CQ, Parnell LD, Troen AM, Shen J, Caouette H, Warodomwichit D, Lee YC, Crott JW, Qiu WQ, Rosenberg IH, Tucker KL, Ordovas JM: MAT1A variants are associated with hypertension, stroke, and markers of DNA damage and are modulated by plasma vitamin B-6 and folate. Am J Clin Nutr 2010;91:1377-1386.
10.
Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, Smith CE, Ordovas JM, Li D, Lai CQ: Interactions between genetic variants of folate metabolism genes and lifestyle affect plasma homocysteine concentrations in the Boston Puerto Rican population. Public Health Nutr 2011;14:1805-1812.
11.
Janula A, Marek B, Kajdaniuk D, Sierek K, Borgiel-Marek H, Kos-Kudla B, Gatnar A, Gnot R, Strzyzewski A, Zeka G, Wyrwas-Belz U: Homocysteine and diabetes (in Polish). Wiad Lek 2005;58:319-323.
12.
Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE: Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009;58:1921-1928.
13.
Yang WY, Lu JM, Weng JP, Jia WP, Ji LN, Xiao JZ, Shan ZY, Liu J, Tian HM, Ji QH, Zhu DL, Ge JP, Lin LX, Chen L, Guo XH, Zhao ZG, Li Q, Zhou ZG, Shan GL, He J: Disorders CNDM: prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
14.
Huang T, Bhulaidok S, Cai ZZ, Xu TC, Xu F, Wahlqvist ML, Li D: Plasma phospholipids n-3 polyunsaturated fatty acid is associated with metabolic syndrome. Mol Nutr Food Res 2010;54:1628-1635.
15.
Araki A, Sako Y: Determination of free and total homocysteine in human-plasma by high-performance liquid-chromatography with fluorescence detection. J Chromatogr Biomed 1987;422:43-52.
16.
Lai CQ, Tucker KL, Parnell LD, Adiconis M, Garcia-Bailo B, Griffith J, Meydani M, Ordovas JM: PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases - the Boston Puerto Rican Health Study. Diabetes 2008;57:809-816.
17.
Box GEP, Cox DR: An analysis of transformations. J Roy Stat Soc B 1964;26:211-252.
18.
Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
19.
Meyer K, Fredriksen A, Ueland PM: High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser desorption/ionization mass spectrometry. Clin Chem 2004;50:391-402.
20.
Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
21.
DeVos L, Chanson A, Liu ZH, Ciappio ED, Parnell LD, Mason JB, Tucker KL, Crott JW: Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr 2008;88:1149-1158.
22.
Sunder-Plassmann G, Födinger M: Genetic determinants of the homocysteine level. Kidney Int Suppl 2003;63:S141-S144.
23.
Ukinc K, Ersoz HO, Karahan C, Erem C, Eminagaoglu S, Hacihasanoglu AB, Yilmaz M, Kocak M: Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009;36:255-261.
24.
Hoogeveen EK, Kostense PJ, Beks PJ, MacKaay AJC, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus - a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-138.
25.
Ndrepepa G, Kastrati A, Braun S, Koch W, Kolling K, Mehilli J, Schomig A: Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc 2008;18:66-73.
26.
Buysschaert M, Wallemacq PE, Dramais AS, Hermans MP: Hyperhomocysteinemia in type 2 diabetes - relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23:1816-1822.
27.
Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y, Nishizawa Y: Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001;24:533-538.
28.
Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJG, Odekerken DAM, Stehouwer CDA, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM - determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-132.
29.
Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins - the atherosclerosis risk in communities (ARIC) study. Circulation 1998;98:204-210.
30.
Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C: Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55:1028-1035.
31.
Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, Stehouwer CD, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-132.
32.
Jacobs RL, House JD, Brosnan ME, Brosnan JT: Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998;47:1967-1970.
33.
Parvanova A, Iliev I, Dimitrov BD, Arnoldi F, Zaletel J, Remuzzi G, Ruggenenti P: Hyperhomocysteinemia and increased risk of retinopathy - a cross-sectional, case-control study in patients with type 2 diabetes. Diabetes Care 2002;25:2361.
34.
Noiri E, Taguchi J, Nakao A, Fujita T: MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes - analysis in Japanese male hemodialysis patients. Diabetes Care 2000;23:260.
35.
Ksiazek P, Bednarek-Skublewska A, Buraczynska M: The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monitor 2004;10:BR47-BR51.
36.
Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mahjoub T, Vaxillaire M, Almawi WY: MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007;75:99-106.
37.
Rahimi M, Hasanvand A, Rahimi Z, Vaisi-Raygani A, Mozafari H, Rezaei M, Zargooshi J, Najafi F, Shakiba E: Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem 2010;43:1333-1339.
38.
Sun JH, Xu YC, Zhu YL, Lu HY: Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004;64:185-190.
39.
Nemr R, Salman RA, Jawad LH, Juma EA, Keleshian SH, Almawi WY: Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs. Clin Chem Lab Med 2010;48:1091-1094.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.